A cell-active cyclic peptide targeting the Nrf2/Keap1 protein–protein interaction

Development of constrained peptide inhibitors targeting an oncogenic E3 ubiquitin ligase

Front Cover: Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance (ChemMedChem 2/2023)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance

A fragment-based approach leading to the discovery of inhibitors of CK2α with a novel mechanism of action.

Development of small cyclic peptides targeting the CK2α/β interface

Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.

Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).

Chemical probes targeting the kinase CK2: a journey outside the catalytic box.

General dual functionalisation of biomacromolecules via a cysteine bridging strategy